PAPER Correia SC, Santos RX, Perry G, Zhu X, Moreira PI, Smith MA

Mitochondria: the missing link between preconditioning and neuroprotection.

J Alzheimers Dis. 2010;20 Suppl 2:S475-85. PubMed: 20463394

PAPER Coskun PE, Wyrembak J, Derbereva O, Melkonian G, Doran E, Lott IT, Head E, Cotman CW, Wallace DC

Systemic mitochondrial dysfunction and the etiology of Alzheimer's disease and down syndrome dementia.

J Alzheimers Dis. 2010;20 Suppl 2:S293-310. PubMed: 20463402

PAPER Lee do, Lee KS, Lee HJ, Kim do, Noh YH, Yu K, Jung HY, Lee SH, Lee JY, Youn YC, Jeong Y, Kim DK, Lee WB, Kim SS

Activation of PERK signaling attenuates Abeta-mediated ER stress.

PLoS One. 2010;5(5):e10489. PubMed: 20463975

PAPER Lauterbach EC, Shillcutt SD, Victoroff J, Coburn KL, Mendez MF

Psychopharmacological neuroprotection in neurodegenerative disease: heuristic clinical applications.

J Neuropsychiatry Clin Neurosci. 2010 Spring;22(2):130-54. PubMed: 20463108

PAPER Dragicevic N, Mamcarz M, Zhu Y, Buzzeo R, Tan J, Arendash GW, Bradshaw PC

Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer's transgenic mice.

J Alzheimers Dis. 2010;20 Suppl 2:S535-50. PubMed: 20463404

PAPER Giralt A, Friedman HC, Caneda-Ferrón B, Urbán N, Moreno E, Rubio N, Blanco J, Peterson A, Canals JM, Alberch J

BDNF regulation under GFAP promoter provides engineered astrocytes as a new approach for long-term protection in Huntington's disease.

Gene Ther. 2010 Oct;17(10):1294-308. PubMed: 20463759

PAPER Chambers JK, Kuribayashi H, Ikeda S, Une Y

Distribution of neprilysin and deposit patterns of Abeta subtypes in the brains of aged squirrel monkeys (Saimiri sciureus).

Amyloid. 2010 Jun;17(2):75-82. PubMed: 20462366

PAPER Shang YC, Chong ZZ, Hou J, Maiese K

Wnt1, FoxO3a, and NF-kappaB oversee microglial integrity and activation during oxidant stress.

Cell Signal. 2010 Sep;22(9):1317-29. PubMed: 20462515

PAPER Greco T, Fiskum G

Neuroprotection through stimulation of mitochondrial antioxidant protein expression.

J Alzheimers Dis. 2010;20 Suppl 2:S427-37. PubMed: 20463397

PAPER Shi P, Wei Y, Zhang J, Gal J, Zhu H

Mitochondrial dysfunction is a converging point of multiple pathological pathways in amyotrophic lateral sclerosis.

J Alzheimers Dis. 2010;20 Suppl 2:S311-24. PubMed: 20463400

PAPER Horowitz MP, Greenamyre JT

Mitochondrial iron metabolism and its role in neurodegeneration.

J Alzheimers Dis. 2010;20 Suppl 2:S551-68. PubMed: 20463401

PAPER Morais VA, De Strooper B

Mitochondria dysfunction and neurodegenerative disorders: cause or consequence.

J Alzheimers Dis. 2010;20 Suppl 2:S255-63. PubMed: 20463408

PAPER Sasaki J, Kofuji S, Itoh R, Momiyama T, Takayama K, Murakami H, Chida S, Tsuya Y, Takasuga S, Eguchi S, Asanuma K, Horie Y, Miura K, Davies EM, Mitchell C, Yamazaki M, Hirai H, Takenawa T, Suzuki A, Sasaki T

The PtdIns(3,4)P(2) phosphatase INPP4A is a suppressor of excitotoxic neuronal death.

Nature. 2010 May 27;465(7297):497-501. PubMed: 20463662

ApoE

ANTIBODY polyclonal manufacturer cat# LS-B2390<br />manufactured by LifeSpan Biosciences Immunogen = Synthetic peptide (C-V G T S A A P V P S D N H) from C-terminus of human APOE liquid, TBS, azide, BSA, affinity purified Apolipoprotein E IgG Apolipoproteins

ApoE

ANTIBODY polyclonal manufacturer cat# LS-B2368<br />manufactured by LifeSpan Biosciences Immunogen = Apo E recombinant protein liquid, PBS, azide, affinity purified Apolipoprotein E IgG Apolipoproteins Autogen Bioclear Goat Human ApoE http://alzforum.org/res